• Assure Holdings (IOM) has expanded its operations with its first neuromonitoring case in Nevada
  • The company has signed an agreement to serve eight hospitals in the state
  • It is now operating in twelve states across the U.S.
  • Assure Holdings provides intraoperative neuromonitoring services during invasive surgeries
  • Assure Holdings (IOM) is unchanged trading at $9.30 per share

Assure Holdings (IOM) has expanded its operations with its first neuromonitoring case in Nevada.

It has signed an agreement to serve eight hospitals in the state, primarily in the Las Vegas Metro Area.

It will begin working with five surgeons that specialize in neurosurgery and orthopedic spine surgery who perform approximately 2,000 procedures per year. 

The company is now operating in twelve states: Colorado, Texas, Louisiana, Utah, Pennsylvania, Michigan, South Carolina, Arizona, Kansas, Missouri, Nebraska and Nevada.

John A. Farlinger, Assure’s Executive Chairman and CEO, stated,

“We expect to grow rapidly in Nevada and are confident in our ability to take advantage of sizeable business development opportunities in the state. On a per capita basis, Las Vegas is among the largest spine surgery markets in the nation. Over the next year, we anticipate that Nevada will be among Assure’s fastest-growing markets.”

Assure Holdings provides intraoperative neuromonitoring services during invasive surgeries.

Assure Holdings (IOM) is unchanged trading at $9.30 per share as of 10:45 am ET.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.